In a cohort study with type 2 diabetes patients, oral administration of OSA (1 g/day, 60 days) induced significant increases in circulating insulin and C-peptide concomitant with a significant reduction in blood glucose levels [32]. This evidence concerns the gene INS and obstructive sleep apnea syndrome.